| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $10.79 | - | - |
| Q1'26 | $8.79 | $8.91 | +1.4% |
| Q4'25 | $12.93 | $13.36 | +3.3% |
| Q3'25 | $10.66 | $11.15 | +4.6% |
| Q2'25 | $9.60 | $10.09 | +5.1% |
| Q1'25 | $7.88 | $8.19 | +3.9% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.0B | - | - |
| Q1'26 | $951M | $947M | -0.4% |
| Q4'25 | $1.1B | $1.1B | +1.3% |
| Q3'25 | - | $1.0B | - |
| Q2'25 | - | $983M | - |
| Q1'25 | - | $884M | - |
Market Data
MTD is currently trading at $1095.92, giving Mettler-Toledo International Inc. a market cap of 22.29B and a P/E ratio of 25.5. Today's range spans $1088.51–$1106.86, with shares opening at $1098.46 and moving down $7.17 (0.6%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL).
Over the past year MTD has traded between $1023.05 and $1525.17 - the current price is +7.1% off the 52-week low and -28.1% from the high.
Sector rotation is working against MTD - large-cap, Healthcare, 22.29B market cap. Technical score 27/100 (SELL), sentiment neutral (-/100), price $1095.92 (near 52-week lows). (P/E: 25.5) When capital rotates out of a sector, large-cap names with bearish technicals are the first to absorb the selling. Annual range $1023.05–$1525.17 frames where the next potential demand zone resides.
Analyst coverage for MTD becomes a double-edged factor in a SELL phase: at 22.29B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 27/100 technical reading and neutral sentiment (-/100) at $1095.92 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $1023.05–$1525.17 range establishes where that repricing lands.
Most recent articles, ranked by recency (click to expand).
Sentiment gathered from recent headlines